US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

IBRX ImmunityBio Inc

7.68

-0.07 (-0.90%)

17 May 2024 - Cerrado

Retrasado por 15 minutos

Form D - Notice of Exempt Offering of Securities

ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas ImmunityBio.

ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas ImmunityBio.

Noticias sobre ImmunityBio Inc IBRX

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
Viernes 17 de Mayo 2024 (2 días hace) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 9 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
Martes 7 de Mayo 2024 (2 semanas hace) • Business Wire

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
Jueves 2 de Mayo 2024 (2 semanas hace) • Business Wire

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
Martes 30 de Abril 2024 (3 semanas hace) • Business Wire

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
Miércoles 24 de Abril 2024 (3 semanas hace) • Business Wire

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Lunes 22 de Abril 2024 (4 semanas hace) • Business Wire

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
Miércoles 6 de Marzo 2024 (2 meses hace) • Business Wire

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Martes 5 de Marzo 2024 (2 meses hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 26 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 26 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 26 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Más de ImmunityBio Inc Artículos de Noticias

LeeWay Services

Leverage DAX X6 Total Re...

Meid Bank Private

Wisdomtree International...

Fidelity International M...

decentral.games [OLD]

Vontobel Financial Produ...

Yieldmax Coin Option Inc...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones